日报更新时间：
周报更新时间：04-11 03:39
今开价：205.35
最高价：207.54
成交量：229293.0
昨收价：206.1
最低价：202.75
最新价：207.02
中文名称：雷普里根
英文名称：Repligen
行业：医疗
简介：Repligen Corporation是供应生物制药关键产品的领军者
电话：1-781-2500111
Repligen Corporation是一家生命科学公司，主要从事在生产单株抗体及其他生物制药时使用的生物制剂&耗材产品的开发、制造和销售。 Repligen公司生产各种型式的蛋白质A(Protein A)，一种关键试剂，应用在单株抗体分离及纯化的生化程序。 Repligen提供各种生长因子与细胞过滤产品，应用在生化程序中的发酵步骤，来增加细胞生长及生产率，以及提供层析技术产品，应用在生物产品纯化程序。 Repligen生产和销售层析技术产品，包括生物纯化用的OPUS预注管柱、以及专属蛋白质A媒介与质控试剂。 Repligen公司拥有治疗性核心产品，包括治疗弗瑞德瑞克氏失调症基因(FRDA)的组织蛋白去乙醯抑制剂；以及RG1068，是一种已发展成为新型显像剂的合成人体激素，应用在运用核磁共振影像(MRI)来为胰脏炎及其他胰脏疾病患者检测胰腺管异常。 Repligen提供交替切流式系统，一种过滤装置，用来改善生化程序中发酵步骤的产品产率。Repligen Corporation通过直销或经销商方式，销售其产品给全球各种生命科学公司、生物制药生产企业、委外代工服务业(CMO)。Repligen Corporation(RGEN)收购、剥离： 2008年，Repligen剥离某些知识产权给百时美施贵宝（Bristol-Myers Squibb）； 2011年，Repligen以2640万美金收购Novozymes(OMX:NZYM B)的生物制品资产； 2016年12月，Repligen(RGEN)将以3900万美元现金收购TangenX Technology。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-14 | Snodgres Jon | Chief Financial Officer | Sell | 295 | 85.95 |
| 2019-06-16 | Dawes (Karen A) | Director | Sell | 1295 | 77.35 |
| 2019-06-16 | Dawes (Karen A) | Director | Buy | 20000 | 4.96 |
| 2019-05-22 | Cooper (Glenn L) | Director | Sell | 4734 | 66.91 |
| 2019-05-22 | Cooper (Glenn L) | Director | Buy | 24000 | 5.00 |
| 2019-05-22 | Cooper (Glenn L) | Director | Sell | 266 | 67.53 |
| 2019-05-14 | Ryan (Thomas F Jr) | Director | Buy | 923 | -- |
| 2019-05-14 | Muir (Glenn P) | Director | Buy | 923 | -- |
| 2019-05-14 | Barthelemy (Nicolas M) | Director | Buy | 923 | -- |
| 2019-05-14 | Dawes (Karen A) | Director | Buy | 1292 | -- |
| 2019-05-14 | Cooper (Glenn L) | Director | Buy | 923 | -- |
| 2019-05-14 | Cox (John G) | Director | Buy | 923 | -- |
| 2019-05-12 | Kuriyel (Ralf) | Officer | Buy | 8000 | -- |
| 2019-05-12 | Snodgres Jon | Chief Financial Officer | Buy | 8000 | -- |
| 2019-03-24 | Snodgres Jon | Chief Financial Officer | Sell | 5458 | 58.45 |
| 2019-03-24 | Snodgres Jon | Chief Financial Officer | Sell | 1009 | 59.05 |
| 2019-03-17 | Hunt (Anthony John) | Chief Executive Officer | Sell | 4009 | 60.45 |
| 2019-03-17 | Hunt (Anthony John) | Chief Executive Officer | Sell | 500 | 60.91 |
| 2019-03-17 | Hunt (Anthony John) | Chief Executive Officer | Sell | 10041 | 59.24 |
| 2019-03-04 | Snodgres Jon | Chief Financial Officer | Sell | 2645 | 58.52 |
| 2019-03-04 | Kuriyel (Ralf) | Officer | Sell | 2240 | 58.53 |
| 2019-03-04 | Hunt (Anthony John) | Chief Executive Officer | Sell | 13000 | 58.50 |
| 2019-02-28 | Kuriyel (Ralf) | Officer | Buy | 4700 | -- |
| 2019-02-28 | Snodgres Jon | Chief Financial Officer | Buy | 4700 | -- |
| 2019-02-27 | Hunt (Anthony John) | Chief Executive Officer | Buy | 22681 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Lord, Abbett & Co LLC | 710088 | 1.48% | -23203 | -3.16% | 2019-03-31 |
| Hartford Funds Management Company, LLC | 1547553 | 3.00% | -6567 | -0.42% | 2019-07-31 |
| Conestoga Capital Advisors, LLC | 1637430 | 3.41% | 21393 | 1.32% | 2019-03-31 |
| Fred Alger Management Inc | 1643045 | 3.42% | 548054 | 50.05% | 2019-03-31 |
| State Street Corporation | 1930767 | 4.02% | -12397 | -0.64% | 2019-03-31 |
| Wellington Management Company LLP | 2212559 | 4.61% | 256717 | 13.13% | 2019-03-31 |
| Vanguard Group Inc | 4115290 | 8.57% | 84619 | 2.10% | 2019-03-31 |
| BlackRock Fund Advisors | 4695353 | 9.11% | -475748 | -9.20% | 2019-07-31 |
| BlackRock Inc | 5650666 | 11.77% | 66580 | 1.19% | 2019-03-31 |
| Macquarie Group Ltd | 1120124 | 2.33% | 54944 | 5.16% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1169999 | 2.27% | 177 | 0.02% | 2019-07-31 |
| OppenheimerFunds Inc | 1082943 | 2.26% | 89226 | 8.98% | 2019-03-31 |
| Delaware Management Company | 778233 | 1.51% | -95123 | -10.89% | 2019-07-31 |
| Northern Trust Investments Inc | 794436 | 1.54% | 24038 | 3.12% | 2019-07-31 |
| Jackson National Asset Management LLC | 821807 | 1.59% | 130831 | 18.93% | 2019-07-31 |
| SSGA Funds Management Inc | 904310 | 1.75% | -2176 | -0.24% | 2019-07-31 |
| Stephens Inv Mgmt Group LLC | 857178 | 1.79% | -1052 | -0.12% | 2019-03-31 |
| Dimensional Fund Advisors, Inc. | 940663 | 1.96% | -71419 | -7.06% | 2019-03-31 |
| Invesco Ltd (OFI / OppenheimerFunds) | 1019589 | 1.98% | -1165363 | -53.34% | 2019-07-31 |
| Federated Investors Inc | 950414 | 1.98% | 8641 | 0.92% | 2019-03-31 |
| Macquarie Investment Management | 739178 | 1.49% | -97062 | -11.61% | 2019-07-31 |
| Amvescap Plc. | 2119043 | 4.41% | -196664 | -8.49% | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 5800597 | 12.08% | -21501 | -0.37% | 2019-05-31 |
| Geode Capital Management, LLC | 907398 | 1.92% | 497885 | 121.58% | 2018-12-31 |
| OFI Global Asset Management, Inc. | 938224 | 2.14% | -1185817 | -55.83% | 2019-04-30 |
| Dimensional Fund Advisors LP | 795052 | 1.81% | -2184 | -0.27% | 2019-03-31 |
| Invesco Advisers, Inc. | 731064 | 1.67% | -53093 | -6.77% | 2019-02-28 |
| TimesSquare Capital Management, LLC | 803991 | 1.83% | -1272515 | -61.28% | 2018-09-30 |
| Ameriprise Financial Inc | 895252 | 2.04% | -2139 | -0.24% | 2018-09-30 |
| William Blair Investment Management, LLC | 1363109 | 3.11% | -443195 | -24.54% | 2018-09-30 |
| Wells Fargo & Co | 804762 | 1.83% | -2341 | -0.29% | 2018-09-30 |
| Invesco Advisers, Inc | 1539704 | 3.51% | 267168 | 20.99% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 1126164 | 2.57% | 67203 | 6.35% | 2018-06-30 |
| Delaware Management Business Trust | 1107691 | 2.53% | 121157 | 12.28% | 2018-06-30 |
| Ranger Investment Management LP | 848989 | 1.94% | 157567 | 22.79% | 2018-06-30 |
| Fidelity Management and Research Company | 907513 | 2.07% | -- | -- | 2018-06-30 |
| Palisade Capital Management LLc | 910704 | 2.08% | 148660 | 19.51% | 2018-06-30 |
| Mackenzie Investments | 946366 | 2.16% | 6300 | 0.67% | 2018-03-31 |
| FMR Inc | 907513 | 2.07% | -- | -- | 2018-06-30 |
| State Street Corp | 1753758 | 4.00% | 154164 | 9.64% | 2018-06-30 |
| Wells Capital Management Inc. | 730980 | 1.67% | 68110 | 10.28% | 2018-06-30 |
| Federated Global Inv Mgmt Corp | 930956 | 2.13% | 70396 | 8.18% | 2018-03-31 |
| Schroder Investment Management North America Inc. | 1284908 | 9.37% | 774950 | 151.96% | 2018-06-30 |
| William Blair Investment Mgmt | 556932 | 1.27% | 17500 | 3.24% | 2018-07-31 |
| Columbia Mangmt Investment Advisers, LLC | 555941 | 1.27% | 32650 | 6.24% | 2018-03-31 |
| Northern Trust Investments N A | 516755 | 1.18% | 4174 | 0.81% | 2018-03-31 |
| Invesco Ltd | 1667763 | 4.93% | -326626 | -16.38% | 2016-12-30 |
| Macquarie Investment Management Limited | 752433 | 1.73% | 752433 | -- | 2017-09-30 |
| Wells Fargo Funds Management LLC | 561378 | 1.29% | 70844 | 14.44% | 2017-11-30 |
| Kalmar Investments Inc | 661607 | 1.96% | 248929 | 60.32% | 2016-09-30 |
| Renaissance Technologies Corp | 1077700 | 3.19% | -47104 | -4.19% | 2016-09-30 |
| Columbia Wanger Asset Management LLC | 559471 | 1.65% | -241406 | -30.14% | 2016-09-30 |
| BlackRock, Inc. | 3361458 | 3.00% | 84271752 | 0.10% | 1999-11-30 |
| Invesco Ltd. | 1727787 | 3.00% | 43315620 | -- | 1999-11-30 |
| FMR LLC | 2532805 | 3.00% | 63497421 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| T. Rowe Price QM US Small-Cap Gr Eq Fd | 422500 | 0.82% | 12100 | 2.95% | 2019-06-30 |
| Delaware Sm-Cap Core Eq-UBS | 739178 | 1.43% | -97062 | -11.61% | 2019-06-30 |
| iShares Russell 2000 ETF | 1041523 | 2.02% | 9003 | 0.87% | 2019-07-30 |
| Vanguard Small Cap Index | 1085752 | 2.11% | -14024 | -1.28% | 2019-06-30 |
| Conestoga Small Cap | 1136175 | 2.20% | 24850 | 2.24% | 2019-05-31 |
| Vanguard Total Stock Market Index Fund | 1161028 | 2.25% | 229 | 0.02% | 2019-06-30 |
| Hartford MidCap Fund | 1322365 | 2.57% | -- | -- | 2019-06-30 |
| Alger Small Cap Focus Fund | 1626412 | 3.16% | 160876 | 10.98% | 2019-05-31 |
| iShares Core S&P Small-Cap ETF | 2537385 | 4.92% | 2442 | 0.10% | 2019-07-30 |
| Delaware Small Cap Core Fund | 739178 | 1.43% | -94973 | -11.39% | 2019-06-30 |
| Invesco Oppenheimer Discovery Fund | 738863 | 1.43% | 28040 | 3.94% | 2019-06-30 |
| Vanguard Small Cap Growth Index Fund | 622784 | 1.21% | -1149 | -0.18% | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 434965 | 0.84% | 5685 | 1.32% | 2019-07-30 |
| SPDR | 443207 | 0.86% | 8664 | 1.99% | 2019-07-31 |
| Lord Abbett Developing Growth Fund | 486029 | 0.94% | 2707 | 0.56% | 2019-05-31 |
| Ranger Small Cap Tr | 529955 | 1.03% | -87605 | -14.19% | 2019-03-31 |
| Federated Kaufmann Fund | 550000 | 1.07% | -- | -- | 2019-03-31 |
| Vanguard Extended Market Index Fund | 576657 | 1.12% | 552 | 0.10% | 2019-06-30 |
| Invesco Small Cap Growth Fund | 596109 | 1.16% | -- | -- | 2019-06-30 |
| iShares S&P Small-Cap 600 Growth ETF | 611238 | 1.19% | -- | -- | 2019-07-30 |
| Vanguard Explorer Fund | 412603 | 0.86% | -- | -- | 2019-03-31 |
| Fidelity | 430986 | 0.90% | -73200 | -14.52% | 2019-04-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | 2476851 | 5.16% | -20864 | -0.84% | 2019-05-23 |
| iShares Core S&P US Total Market ETF | 2476413 | 5.16% | -- | -- | 2019-05-30 |
| iShares US Small Cap ETF (CAD-Hedged) | 796696 | 1.66% | -1341 | -0.17% | 2019-05-30 |
| Vanguard Small Cap Index Fund | 1031431 | 2.18% | 3723 | 0.36% | 2019-04-30 |
| Oppenheimer Discovery Fund | 651623 | 1.48% | -- | -- | 2019-03-31 |
| JNL/Invesco Small Cap Growth Fund | 406295 | 0.93% | 2441 | 0.60% | 2018-12-31 |
| Invesco S&P SmallCap Health Care ETF | 368553 | 0.84% | -- | -- | 2019-02-27 |
| Oppenheimer International Small-Md Co Fd | 1054000 | 2.40% | -156410 | -12.92% | 2018-11-30 |
| iShares Nasdaq Biotechnology ETF | 492345 | 1.12% | -966 | -0.20% | 2018-11-30 |
| Quadrus Mackenzie US Mid Cap Gr Cl | 397155 | 0.91% | -337237 | -45.92% | 2018-05-31 |
| Mackenzie US Mid Cap Growth Class | 397155 | 0.91% | -337237 | -45.92% | 2018-05-31 |
| iShares Nasdaq Biotechnology | 495071 | 1.17% | -942 | -0.19% | 2018-09-12 |
| JNL/Invesco Small Cap Growth B | 401117 | 0.92% | 91620 | 29.60% | 2018-06-30 |
| Vanguard Explorer Inv | 412603 | 0.94% | -- | -- | 2018-06-30 |
| Conestoga Small Cap Investors | 1232300 | 2.81% | 29300 | 2.44% | 2018-07-31 |
| Oppenheimer International Small-Mid Co A | 1210410 | 2.76% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 985951 | 2.25% | -- | -- | 2018-07-31 |
| Delaware Small Cap Core A | 869500 | 1.98% | 57700 | 7.11% | 2018-07-31 |
| Ranger Small-Cap Fund | 848887 | 1.94% | 157567 | 22.79% | 2018-06-30 |
| iShares S&P Small-Cap 600 Growth | 656634 | 1.56% | 8325 | 1.28% | 2018-09-12 |
| Alger Small Cap Focus A | 608248 | 1.39% | 109273 | 21.90% | 2018-06-30 |
| Invesco Small Cap Growth A | 595168 | 1.36% | 126691 | 27.04% | 2018-06-30 |
| PowerShares S&P SmallCap Health Care ETF | 475591 | 1.14% | 9960 | 2.14% | 2018-09-13 |
| Federated Kaufmann R | 550000 | 1.26% | -160000 | -22.54% | 2018-06-30 |
| Vanguard Extended Market Idx Inv | 493783 | 1.13% | -- | -- | 2018-07-31 |
| Oppenheimer Discovery A | 450143 | 1.03% | 34410 | 8.28% | 2018-07-31 |
| iShares Russell 2000 Growth | 376793 | 0.89% | -363 | -0.10% | 2018-09-12 |
| William Blair Small-Mid Cap Gr I | 440941 | 1.01% | 13600 | 3.18% | 2018-07-31 |
| T. Rowe Price QM US Small-Cap Growth Eq | 324700 | 0.74% | 20400 | 6.70% | 2018-06-30 |
| Wells Fargo Emerging Growth Admin | 341512 | 0.78% | 34686 | 11.30% | 2018-06-30 |
| AMG TimesSquare Small Cap Growth Instl | 320000 | 0.73% | -35000 | -9.86% | 2018-06-30 |
| Vanguard Tax-Managed Small Cap Adm | 316643 | 0.72% | 9300 | 3.03% | 2018-06-30 |
| Pru Ret Small Cap Growth/TimesSquare SP | 339000 | 0.78% | -- | -- | 2018-03-31 |
| Lord Abbett Developing Growth A | 471539 | 1.08% | -26770 | -5.37% | 2017-10-31 |
| DFA US Micro Cap I | 327523 | 0.75% | -- | -- | 2017-10-31 |
| DFA US Small Cap I | 240109 | 0.71% | -- | -- | 2016-12-31 |
| Met Invt Ser Invesco Small Cap Gr A | 235032 | 0.69% | -8266 | -3.40% | 2016-12-31 |
| iShares Core S&P Small-Cap (AU) | 852553 | 2.20% | 5740 | 0.70% | 2015-11-18 |
| Oppenheimer International Small Co Fund | 839100 | 2.50% | -- | -- | 2015-09-30 |
| SPDR® S&P Biotech ETF | 648741 | 1.60% | 4244 | 0.70% | 2015-11-19 |
| iShares Russell 2000 (AU) | 520979 | 1.40% | -327 | -0.10% | 2015-11-18 |
| RS Small Cap Growth Fund | 496400 | 1.50% | -148040 | -23.00% | 2015-09-30 |
| DFA U.S. Micro Cap Portfolio | 375025 | 1.10% | -- | -- | 2015-09-30 |
| Wells Fargo Advantage Emerging Gr Fund | 369250 | 1.10% | -360 | -0.10% | 2015-09-30 |
| PowerShares Dynamic Biotech&Genome Port | 367104 | 0.90% | -- | -- | 2015-11-19 |
| ASTON/TAMRO Small Cap Fund | 363630 | 1.10% | -41851 | -10.30% | 2015-09-30 |
| Fidelity® Select Biotechnology Portfolio | 1861315 | 5.70% | -- | -- | 2015-09-30 |
| Glenn L. Cooper | Currently, Glenn L. Cooper is Chairman of Lascaux Media LLC. Dr. Cooper is also on the board of Repligen Corp. In his past career he held the position of Executive Chairman at Fortress Biotech, Inc., President & Chief Executive Officer of Progenitor, Inc., Chief Operating Officer & Executive Vice President for Sphinx Pharmaceuticals Corp, Chairman & Chief Executive Officer for Indevus Pharmaceuticals, Inc. and Director-Clinical Research at Lilly Research Center Ltd. He received an undergraduate degree from Harvard College and a doctorate from Tufts University School of Medicine. |
|---|---|
| Karen A. Dawes | Karen A. Dawes founded Knowledgeable Decisions LLC. Currently, Ms. Dawes holds the position of Chairman of Repligen Corp. and President of Knowledgeable Decisions LLC. Ms. Dawes is also on the board of Assertio Therapeutics, Inc., Symbiomix Therapeutics LLC, Seaside Therapeutics, Inc. and Medicines 360. Karen A. Dawes previously occupied the position of Chairman of PDL BioPharma, Inc., Vice President-Marketing of Pfizer Inc. Vice President-Commercial Operations at Genetics Institute LLC and Senior Vice President-Global Strategic Marketing at Wyeth Corp. (both are subsidiaries of Pfizer Inc.) and Senior Vice President & Head-US Business Group at Bayer Corp. Karen A. Dawes received a graduate degree and an undergraduate degree from Simmons College (Massachusetts) and an MBA from Harvard University. |
| Nicolas M. Barthelemy | Nicolas M. Barthelemy is on the board of Repligen Corp. and 4 other companies. Mr. Barthelemy previously held the position of Chief Executive Officer & Director at Biotheranostics, Inc., Vice President-Manufacturing at Biogen, Inc., General Manager at Research Triangle Park, Senior Project Engineer-Vaccine Technology at Merck & Co., Inc., President-Cell Systems Division at Invitrogen Corp. and President-Global Commercial Operations at Life Technologies Corp. He received a graduate degree from the University of California, Berkeley and an undergraduate degree from Ecole Sup�0�1�0�8rieure de Physique et de Chimie de Paris. |
| Karen A. Dawes | Karen A. Dawes founded Knowledgeable Decisions LLC. Currently, Ms. Dawes holds the position of Chairman of Repligen Corp. and President of Knowledgeable Decisions LLC. Ms. Dawes is also on the board of Assertio Therapeutics, Inc., Symbiomix Therapeutics LLC, Seaside Therapeutics, Inc. and Medicines 360. Karen A. Dawes previously occupied the position of Chairman of PDL BioPharma, Inc., Vice President-Marketing of Pfizer Inc. Vice President-Commercial Operations at Genetics Institute LLC and Senior Vice President-Global Strategic Marketing at Wyeth Corp. (both are subsidiaries of Pfizer Inc.) and Senior Vice President & Head-US Business Group at Bayer Corp. Karen A. Dawes received a graduate degree and an undergraduate degree from Simmons College (Massachusetts) and an MBA from Harvard University. |
| Jon K. Snodgres | Jon K. Snodgres is Secretary, Chief Financial & Accounting Officer at Repligen Corp. In his past career Mr. Snodgres occupied the position of Vice President-Finance at Thermo Fisher Scientific, Inc. and Chief Financial Officer at MAQUET Cardiovascular LLC. Mr. Snodgres received an undergraduate degree from Northern Arizona University. |
| Thomas F. Ryan | Thomas F. Ryan is on the board of Repligen Corp., Boston College, New York Independent System Operator, Inc. and Mellon Asset Management. In his past career he occupied the position of Chairman for Kidder, Peabody & Co., Inc. and President & Chief Operating Officer for American Stock Exchange LLC. Mr. Ryan received an undergraduate degree from Boston College and an undergraduate degree from Boston Latin School. |
| Glenn P. Muir | Glenn P. Muir is on the board of Repligen Corp., Neuronetics, Inc. and G1 Therapeutics, Inc. and Member of Massachusetts Society of Certified Public Accountants, Inc. and Member of The American Institute of Certified Public Accountants. He previously was Executive Vice President-Finance & Administration at Hologic, Inc., Senior Auditor at Arthur Andersen LLP and Chief Financial Officer & VP-Administration at Metallon Engineered Materials Corp. Glenn P. Muir received an undergraduate degree from the University of Massachusetts, a graduate degree from Bentley University and an MBA from Harvard University. |
| Sondra S. Newman | Presently, Sondra S. Newman is Senior Director-Investor Relations at Repligen Corp. Ms. Newman previously held the position of Director-Investor Relations at NitroMed, Inc. |
| Stephen Tingley | Stephen Tingley holds the position of Vice President-Sales of Repligen Corp. Mr. Tingley received an undergraduate degree from the University of Leeds. |
| John G. Cox | Presently, John G. Cox is Executive Chairman for Torque Therapeutics, Inc. He is also on the board of Repligen Corp. and Sigilon Therapeutics, Inc. Mr. Cox previously occupied the position of EVP-Pharmaceutical Operations & Technology at Biogen, Inc. and Executive Vice President for Biogen Idec New Ventures, Inc. (a subsidiary of Biogen, Inc.), Chief Executive Officer & Director at Bioverativ, Inc., Principal at Covance Biotechnology Services, Inc. and Principal at Wyeth Corp. Mr. Cox received an MBA from the University of Michigan, an undergraduate degree from The California State University and an undergraduate degree from Arizona State University. |
| Tony J. Hunt | Tony J. Hunt is President, Chief Executive Officer & Director at Repligen Corp. In the past Mr. Hunt was President-Bioproduction at Life Technologies Corp. and Senior Director-Pharma Programs at Applied Biosystems, Inc. He received an undergraduate degree and a graduate degree from National University of Ireland and an MBA from Questrom School of Business. |
| Glenn P. Muir | Glenn P. Muir is on the board of Repligen Corp., Neuronetics, Inc. and G1 Therapeutics, Inc. and Member of Massachusetts Society of Certified Public Accountants, Inc. and Member of The American Institute of Certified Public Accountants. He previously was Executive Vice President-Finance & Administration at Hologic, Inc., Senior Auditor at Arthur Andersen LLP and Chief Financial Officer & VP-Administration at Metallon Engineered Materials Corp. Glenn P. Muir received an undergraduate degree from the University of Massachusetts, a graduate degree from Bentley University and an MBA from Harvard University. |
| Steve Curran | Presently, Steve Curran occupies the position of Vice President-Global Operations at Repligen Corp. Mr. Curran received an undergraduate degree from Worcester Polytechnic Institute. |
| Ralf Kuriyel | Currently, Ralf Kuriyel holds the position of Senior Vice President-Research & Development at Repligen Corp. In his past career he held the position of Vice President-Research & Development of Pall Life Sciences and Vice President-Field Applications R&D at Pall Corp. He received an undergraduate degree and a graduate degree from Rensselaer Polytechnic Institute. |
| Ken Elmer | Ken Elmer is Global Head-Human Resources at Repligen Corp. Mr. Elmer previously was Vice President-Human Resources at GlassHouse Technologies, Inc., Chief Human Resources Officer for Attune Consulting USA LLC, Chief People Officer for Viant Corp., Senior Vice President-Human Resources of Celerant Consulting, Inc. and Vice President-Human Resources for Cambridge Technology Partners (Massachusetts), Inc. |
| Rachel Goodrich | Currently, Rachel Goodrich is Vice President-Marketing of Repligen Corp. She received an undergraduate degree from the University of the Philippines and a graduate degree from Stanford University. |
| Vikas Gupta | Vikas Gupta is Vice President-Strategy Growth Initiatives at Repligen Corp. Mr. Gupta received a graduate degree from Bentley University. |
| Christine Gebski | Christine Gebski is VP-Product Cell Culture & Chromatography at Repligen Corp. |
| Marc J. Centrella | Marc J. Centrella is Vice President-Business Development & Strategy at Repligen Corp. In the past Mr. Centrella was Senior Director-Corporate Development & Strategy at Becton, Dickinson & Co. and Director-Corporate Development at Catalent Pharma Solutions, Inc. Mr. Centrella received an undergraduate degree from Ramapo College of New Jersey. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论